Judge Rejects Antitrust Challenge To Hatch-Waxman Settlement
In a move that marks a trend toward a legal stamp of approval for settlements between brand-name drug makers and their generic competitors, a federal court in New York has rejected...To view the full article, register now.
Already a subscriber? Click here to view full article